Efficacy of salvage surgery for hepatocellular carcinoma following conversion therapy

doi:10.5306/wjco.v16.i6.107255

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-6)

Sum=0

Jun 24, 2025 (publication date) through Jun 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Jun 24, 2025; 16(6): 107255
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.107255

Table 5 Analysis of postoperative recurrence-free survival-related risk factors

Risk factor	Univariate analysis		Multivariate analysis
Risk factor	HR (95%CI)	P value	HR (95%CI)	P value
Age (≥ 65 years)	3.475 (0.889-13.586)	0.073	-	-
HBsAg (positive)	1.117 (0.237-5.272)	0.889	-	-
EOCG-PS (1)	11.943 (2.310-61.743)	0.003	0.406 (0.027-6.115)	0.515
Child-Pugh class (B)	5.810 (1.521-22.185)	0.010	3.748 (0.390-35.980)	0.252
Vascular invasion (present)	1.676 (0.433-6.487)	0.455	-	-
Conversion therapy cycle (≥ 5 times)	1.567 (0.436-5.637)	0.491	-	-
Number of TACE (≥ 2 times)	2.326 (0.481-11.245)	0.294	-	-
irAEs (present)	0.446 (0.056-3.566)	0.446	-	-
Surgical type (open)	4.256 (0.533-34.003)	0.172	-	-
Surgery time (≥ 200 minutes)	1.580 (0.335-7.448)	0.563	-	-
Intraoperative blood loss (≥ 500 mL)	0.821 (0.174-3.869)	0.803	-	-
Intraoperative blood transfusion (yes)	0.917 (0.257-3.278)	0.894	-	-
Clavien-Dindo class (IIIa-V)	0.037 (0.000-71.508)	0.394	-	-
Post-operative pathology (PCR)	0.171 (0.036-0.811)	0.026	0.073 (0.009-0.571)	0.013
Maximum tumor diameter (≥ 10 cm)	1.537 (0.392 -6.028)	0.537	-	-
Number of tumors (≥ 3)	1.088 (0.306-3.861)	0.897	-	-
WBC count (≥ 4 × 10⁹/L)	1.201 (0.310-4.653)	0.791	-	-
HGB level (≥ 120 g/L)	0.072 (0.009-0.571)	0.013	0.51 (0.018-14.854)	0.701
RBC count (≥ 4.3 × 10¹²/L)	0.194 (0.041-0.916)	0.038	1.816 (0.190-17.317)	0.604
PLT count (≥ 100 × 10⁹/L)	2.200 (0.650-40.842)	0.120	-	-
ALB level (≥ 35 g/L)	0.052 (0.007-0.412)	0.005	0.022 (0.001-0.594)	0.023
ALT level (≥ 40 IU/L)	0.602 (0.127-2.860)	0.523	-	-
AST level (≥ 40 IU/L)	0.777 (0.219-2.756)	0.696	-	-
AFP level (≥ 400 ng/mL)	1.415 (0.365-5.477)	0.615	-	-
Postoperative adjuvant therapy (present)	0.746 (0.213-2.606)	0.646	-	-

HR: Hazard ratio; CI: Confidence interval; HbsAg: Hepatitis B surface antigen; ECOG-PS: Eastern Cooperative Oncology Group performance status; TACE: Transcatheter arterial chemoembolization; irAEs: Immune-related adverse events; PCR: Pathological complete response; WBC: White blood cell count; HGB: Hemoglobin; RBC: Red blood cell count; PLT: Platelet count; ALB: Albumin; ALT: Alanine transaminase; AST: Aspartate transaminase; AFP: Alpha-fetoprotein.

Citation: Zhang SB, Nashan B, Wang YL, Zhang SG. Efficacy of salvage surgery for hepatocellular carcinoma following conversion therapy. World J Clin Oncol 2025; 16(6): 107255
URL: https://www.wjgnet.com/2218-4333/full/v16/i6/107255.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i6.107255